Candriam S.C.A. Novo Cure LTD Transaction History

Candriam S.C.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$56.6 - $89.9 $169 - $269	-3 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$60.15 - $84.52 $180 - $253	3 New	3 $0
Q4 2021 Feb 10, 2022	SELL	$75.08 - $121.99 $225 - $365	-3 Closed	0 $0
Q2 2021 Jul 20, 2021	BUY	$130.4 - $225.58 $130 - $225	1 Added 50.0%	3 $1,000
Q1 2021 Apr 29, 2021	SELL	$124.11 - $190.17 $248 - $380	-2 Reduced 50.0%	2 $0
Q4 2020 Jan 22, 2021	SELL	$112.16 - $174.14 $672 - $1,044	-6 Reduced 60.0%	4 $1,000
Q3 2020 Oct 19, 2020	BUY	$58.05 - $111.31 $58 - $111	1 Added 11.11%	10 $1,000
Q2 2020 Jul 23, 2020	BUY	$57.2 - $74.41 $57 - $74	1 Added 12.5%	9 $1,000
Q1 2020 May 26, 2020	BUY	$57.05 - $95.75 $456 - $766	8 New	8 $1,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.